1 week Ago By Defense World Staff
Geode Capital Management LLC lifted its position in shares of Sana Biotechnology, Inc. ( NASDAQ:SANA – Free Report ) by 0.8% during the 4th quarter, according to its most recent disclosure with the SEC.
The firm owned 3,193,081 shares of the company’s stock after buying an additional 26,601 shares during the period. Geode Capital Management LLC owned 1.43% of Sana Biotechnology worth $5,206,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of SANA. KLP Kapitalforvaltning AS acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth $39,000. Teacher Retirement System of Texas grew its holdings in Sana Biotechnology by 20.
3% in the 4th quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company’s stock valued at $60,000 after buying an additional 6,209 shares during the period. Corient Private Wealth LLC increased its stake in shares of Sana Biotechnology by 161.
7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after acquiring an additional 730,699 shares during the last quarter. Charles Schwab Investment Management Inc.
increased its stake in shares of Sana Biotechnology by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc.
now owns 1,056,512 shares of the company’s stock valued at $1,722,000 after acquiring an additional 8,666 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Sana Biotechnology by 3.0% during the 4th quarter.
Bank of New York Mellon Corp now owns 336,828 shares of the company’s stock worth $549,000 after acquiring an additional 9,905 shares during the period. Institutional investors and hedge funds own 88.23% of the company’s stock.
Analysts Set New Price Targets A number of equities research analysts recently issued reports on SANA shares. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Sana Biotechnology in a report on Thursday.
Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research note on Tuesday, March 18th. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th.
Finally, Jefferies Financial Group assumed coverage on Sana Biotechnology in a research report on Friday, March 14th. They set a “buy” rating and a $7.00 price target for the company.
One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.
80. Sana Biotechnology Stock Performance NASDAQ:SANA opened at $1.77 on Friday.
Sana Biotechnology, Inc. has a twelve month low of $1.26 and a twelve month high of $10.
50. The firm has a market capitalization of $398.29 million, a price-to-earnings ratio of -1.
26 and a beta of 1.78. The firm’s fifty day simple moving average is $2.
12 and its 200 day simple moving average is $2.63. Sana Biotechnology ( NASDAQ:SANA – Get Free Report ) last issued its quarterly earnings data on Monday, March 17th.
The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.
02. On average, analysts predict that Sana Biotechnology, Inc. will post -1.
16 earnings per share for the current year. Sana Biotechnology Company Profile ( Free Report ) Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Articles Five stocks we like better than Sana Biotechnology What Are Dividend Contenders? Investing in Dividend Contenders Markets Think Robinhood Earnings Could Send the Stock Up 3 Ways To Invest In Coffee, Other Than Drinking It Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter ..
